Datascope Corp.
$1.6M 14 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Valneva Austria GMBH
Valneva Austria GMBH reported $1,598,635.84 across General Payments, Research, and Ownership to 1 physicians and teaching hospitals across 541 transactions.
- $1.6M Above-median payer
- All-tracks total
- 541 Above-median volume
- Transactions
- 1 Below-median reach
- Recipients
- −$10.7K
- General Payments vs PY2023
Valneva Austria GMBH reported $1,598,635.84 across all CMS Open Payments tracks (General + Research + Ownership) to 1 physicians and teaching hospitals in Program Year 2024 - ranking #510 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,400.00, averaging $1.6M per recipient.
How Valneva Austria GMBH's $1.6M all-tracks total breaks down
Valneva Austria GMBH's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
15/100
Total payments
F
25/100
Transaction volume
F
14/100
Physician reach
F
10/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer valneva-austria-gmbh Valneva Austria GMBH
$1.6M · #510/1,925 · 0.0% industry · PY2024
- TOT $1.6M
- RANK #510
- SHARE 0.0%
- TXN 541
- RCP 1
- CAT 1
- GEN $1.4K
- ΔGEN −$10.7K
- TOP1 100.0%
- PY 2024
Volume peers
Nearest volume peer: Datascope Corp. ($1.6M)
Valneva Austria GMBH sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Valneva Austria GMBH's CMS-reported General Payments decreased by $10.7K (−88.4%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: VALNEVA AUSTRIA GMBHPY2023: VALNEVA AUSTRIA GMBHPY2024: Valneva Austria GMBH. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $12,113.00
- PY2024
- $1,400.00
What the Data Shows for Valneva Austria GMBH
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Valneva Austria GMBH, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
"Consulting Fee" leads the 1-category general-payment breakdown below at $1.4K (100.0% of General Payments, 1 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Valneva Austria GMBH made 1 types of general payments. "Consulting Fee" is the largest category at $1.4K, 100.0% of General Payments.
How Valneva Austria GMBH divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $1.4K | 1 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,400.00 (100.0%) of $1,400.00 in this company's General Payments records across 1 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Valneva Austria GMBH
The five named recipients with the highest reported General Payments from this company
- 1
Lin Chen
$1,400.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Valneva Austria GMBH ranks #510 of 1,925 by total payments (top 26% by spend) but is notably more concentrated than that alone would suggest -- #130 of 1,838 by HHI (top 7% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Mallinckrodt LLC : $390.2K total payments, HHI 10000
- Rhodes Pharmaceuticals L.P. : $134.9K total payments, HHI 10000
- Medivance, Inc. : $2.0K total payments, HHI 10000
- RaySearch Laboratories AB (publ) : $45.00 total payments, HHI 10000
- Applied Medical Corporation : $80.1K total payments, HHI 10000
- Cook Biotech Incorporated : $609.12 total payments, HHI 10000
- Valneva Austria GMBH (this company) : $1.4K total payments, HHI 10000
- Canon Medical Research USA Inc. : $1.5K total payments, HHI 10000
- Medical Graphics Corporation : $6.4K total payments, HHI 10000
- DENTSPLY DeTrey GmbH : $648.31 total payments, HHI 10000
- Hand Biomechanics Laboratory : $5.0K total payments, HHI 10000
- UCB GmbH : $14.46 total payments, HHI 10000
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Valneva Austria GMBH's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Valneva Austria GMBH.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Valneva Austria GMBH.
Showing 6 of 1,924 companies with CMS-reported payment data.
restor3d, inc.
$1.6M 1,071 recipients
Compare payment profiles
Ethicon US, LLC
$1.6M 15,448 recipients
Compare payment profiles
Grifols Shared Services North America, Inc.
$1.6M 138 recipients
Compare payment profiles
Avita Medical Americas, Llc
$1.6M 2,776 recipients
Compare payment profiles
Veloxis Pharmaceuticals, Inc.
$1.6M 766 recipients
Compare payment profiles
Put this to use
Valneva Austria GMBH ranks #510 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Valneva Austria GMBH sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Valneva Austria GMBH. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.